Bioventus Inc.BVSNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank42
5Y CAGR-14.0%
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

5Y CAGR
-14.0%/yr
Long-term compound
Percentile
P42
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
20257.16-71.4%
202424.99+183.8%
2023-29.82-561.7%
2022-4.51-121.1%
202121.39+40.7%
202015.20-23.6%
201919.89-12.8%
201822.81-
20170.00-
20160.00-